NEW YORK (GenomeWeb News) – PDI today announced it will buy molecular diagnostics company RedPath Integrated Pathology for more than $23 million in cash and stock.

The purchase helps PDI subsidiary Interpace Diagnostics expand its oncology product portfolio with RedPath's PathfinderTG platform, which includes Pathfinder TG Pancreas, a diagnostic test that helps physicians determine cancer risk in pancreatic cysts. That test generates annual revenues of approximately $10 million, said PDI.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.